Loading
MT-228 is an experimental small molecule from Myosin Therapeutics, in preclinical development for undisclosed cancer.
MT-228 is a small molecule from Myosin Therapeutics. A small-molecule inhibitor of non-muscle myosin IIA and IIB (the products of MYH9 and MYH10) being pursued for non-orphan oncology indications. Its furthest stage is preclinical development, for undisclosed cancer. No clinical trial naming it is registered on ClinicalTrials.gov. It has not been shown to work in people.
A small-molecule inhibitor of non-muscle myosin IIA and IIB (the products of MYH9 and MYH10) being pursued for non-orphan oncology indications. Connects to MYH9.
1.MT-228 slips into a pocket on MYH9.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MT-228" OR ABSTRACT:"MT-228") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MT-228, not a curated reading list.
Shares Myosin Therapeutics, MYH9 and the tag pipeline.
Shares Myosin Therapeutics and the tag pipeline.
Shares Myosin Therapeutics and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/